DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Smartwatches still can’t measure blood sugar on their own, but AI-powered CGMs are changing how glucose data is tracked and ...

DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

Diabetes technology news has been off to a fast start this year. Here are some highlights of MedTech Dive’s coverage from ...

Parents of young children with elevated blood sugar now have a new option that does not require a doctor’s prescription. The ...

Omnipod 5 Automated Insulin Delivery System now available in 20 countries worldwide New web-based data platform Omnipod Discover simplifies diabetes insights for users, caregivers, and healthcare ...

A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain ...

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue ...

Last week, the biosensor field reported innovations ranging from medical diagnostics to basic research. Of particular note are the FDA approval of Dexcom's Stelo as the first OTC CGM for ...

Adults in the US who want to measure their blood glucose levels using a wearable sensor will soon be able to buy one over-the-counter (OTC) for the first time. The FDA has cleared Dexcom’s Stelo as ...